Active Surveillance for Methicillin-resistant Staphylococcus aureus (MRSA)
“Methicillin-resistant Staphylococcus aureus infections continue to be significant cause of morbidity and mortality worldwide in both healthcare and community settings. A strategy to reduce the transmission of MRSA in healthcare settings is to conduct active surveillance of patients admitted to hospitals or other healthcare facilities for colonization.”1
Resistance to methicillin among S. aureus isolates is a growing problem: up to 60% of healthcare associated infections in patients in the intensive care unit (ICU) are due to methicillin-resistant S. aureus.2 In fact, MRSA has been identified by the Society for Healthcare Epidemiology of America (SHEA) as one of the two “most out of control” antimicrobial-resistant pathogens in U.S. hospitals (VRE is the other).3 A 2004 study of a surgical ICU that implemented an active surveillance and contact precautions program found that the use of these methods decreased transmission of MRSA from 5% to 0.9%.4
Government and professional organizations are increasingly recommending more proactive procedures to identify, prevent, and control multi-drug resistant organisms (MDROs) such as MRSA.
Active Surveillance Solutions from BD for Methicillin-resistant Staphylococcus aureus
Accurate and timely results enable informed decisions that can help prevent transmission of, and infection with MRSA, avoid excessive costs and improve patient outcomes.
Customize an MRSA active surveillance strategy unique to your institution’s goal In today’s challenging healthcare environment, different institutions have different needs. BD delivers unique testing solutions for comprehensive active surveillance program that focus on:
- Admission
- Transfer
- Discharge
- Surgery
- A patient’s prior history of MRSA colonization
BD uniquely provides a broad array of MRSA surveillance products; the speed and sensitivity of the molecular-based BD GeneOhm™ MRSA ACP assay along with the simple and flexible BBL™ CHROMagar® MRSA II test help reduce healthcare-associated infections.
 |
BD GeneOhm™ MRSA ACP Assay
The BD GeneOhm™ MRSA ACP rapid molecular assay simplifies assay workflow by incorporating enzymatic achromopeptidase (ACP) lysis technology which results in fewer steps and less technologist hands-on time.*
More information on BD GeneOhm™ MRSA ACP Assay |
|
|
 |
BBL™ CHROMagar® MRSA II
BBL™ CHROMagar® MRSAII delivers enhanced performance and flexible workflow for the detection of MRSA from nasal specimens**
More information on BBL™ CHROMagar® MRSA II |
|
